ACADIA PHARMACEUTICALS INC. Deferred Tax Assets, Operating Loss Carryforwards
ACADIA PHARMACEUTICALS INC. (ACAD) had Deferred Tax Assets, Operating Loss Carryforwards of $77.12 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $77.12M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $117.05M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $149.05M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $225.99M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $77.12M 10-K · filed 2026-02-26 |
| 2024-12-31 | $117.05M 10-K · filed 2026-02-26 |
| 2023-12-31 | $149.05M 10-K · filed 2025-02-27 |
| 2022-12-31 | $225.99M 10-K · filed 2024-02-28 |
| 2021-12-31 | $229.48M 10-K · filed 2023-02-28 |
| 2020-12-31 | $218.91M 10-K · filed 2022-03-01 |
| 2019-12-31 | $182.95M 10-K · filed 2021-02-25 |
| 2018-12-31 | $170.48M 10-K · filed 2020-02-27 |
| 2017-12-31 | $163.06M 10-K · filed 2019-02-27 |
| 2016-12-31 | $168.75M 10-K · filed 2018-02-27 |
| 2015-12-31 | $161.28M 10-K · filed 2017-02-28 |
| 2014-12-31 | $168.78M 10-K · filed 2016-02-29 |
| 2013-12-31 | $136.58M 10-K · filed 2015-02-26 |
| 2012-12-31 | $127.89M 10-K · filed 2014-02-27 |
| 2011-12-31 | $118.28M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |